跳至主要内容
临床试验/NCT00060021
NCT00060021已完成不适用

A Randomized, Placebo-Controlled, Blinded Study Of Acupuncture Therapy In Mucositis-Related Pain In Patients Undergoing Hematopoietic Stem Cell Transplantation

National Cancer Institute (NCI)2 个研究点 分布在 1 个国家开始时间: 2003年3月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
试验地点
2

研究概览

简要总结

RATIONALE: Acupuncture may be effective in relieving mucositis-related pain caused by chemotherapy in patients undergoing stem cell transplantation.

PURPOSE: Randomized clinical trial to study the effectiveness of acupuncture in treating mucositis-related pain caused by high-dose chemotherapy in patients who are undergoing stem cell transplantation.

详细描述

OBJECTIVES:

  • Compare the efficacy of acupuncture vs placebo acupuncture in alleviating mucositis-related pain secondary to high-dose chemotherapy, as assessed by total cumulative dose of opioids used and subjective pain scores, in patients undergoing hematopoietic stem cell transplantation.
  • Compare the overall number of patients requiring opioid therapy in these 2 intervention groups.
  • Compare the nausea and vomiting scores of patients in these 2 intervention groups.
  • Compare the sedation score of patients in these 2 intervention groups.
  • Compare the use of other psychotropic medications (e.g., anxiolytics or hypnotics) in patients in these 2 intervention groups.
  • Compare the need for total parenteral nutrition (TPN) and the number of days on TPN experienced by patients in these 2 intervention groups.
  • Compare pruritus and the need for symptomatic treatment in patients in these 2 intervention groups.

OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are stratified according to 9-phenylthiocarbamide/6-n-propylthiouracil (PROP) tasting ability (super-tasters vs non-super-tasters). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Beginning immediately after the development of mucositis pain, patients undergo acupuncture over 30 minutes once daily. Patients also receive standard pain management. Treatment continues until pain is completely resolved in the absence of unacceptable toxicity.
  • Arm II: Patients undergo placebo acupuncture and receive standard pain management as in arm I.

PROJECTED ACCRUAL: A maximum of 45 patients will be accrued for this study within 3 years.

研究设计

研究类型
Interventional
分配方式
Randomized
主要目的
Supportive Care
盲法
Double

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • DISEASE CHARACTERISTICS:
  • Must be undergoing hematopoietic stem cell transplantation (HSCT) through one of the following means:
  • Concurrent enrollment on a HSCT protocol with the Experimental Transplantation & Immunology Branch (ETIB) at the NCI Center for Clinical Research*
  • Receiving HSCT as a compassionate exemption following the clinical guidelines of an ETIB protocol*
  • Directly observed oral or pharyngeal mucositis and/or suspected esophageal mucositis after high-dose chemotherapy
  • No pain unrelated to mucositis requiring use of potent analgesics prior to initiation of high-dose chemotherapy NOTE: *Protocol must be known to generate more than 50% incidence of high-dose chemotherapy-induced mucositis
  • PATIENT CHARACTERISTICS:
  • 18 and over
  • Performance status
  • Not specified
  • Life expectancy
  • Not specified
  • Hematopoietic
  • No history of bleeding disorders
  • PT and PTT normal
  • Not specified
  • No history or evidence of drug addiction or drug-seeking behavior
  • No skin infection at the sites of acupuncture points
  • PRIOR CONCURRENT THERAPY:
  • Biologic therapy
  • See Disease Characteristics
  • Chemotherapy
  • See Disease Characteristics
  • Endocrine therapy
  • Not specified
  • Radiotherapy
  • Not specified
  • Not specified
  • No concurrent anticoagulant therapy

排除标准

  • 未提供

研究者

申办方类型
Nih

研究点 (2)

Loading locations...

相似试验